Among the molecularly targeted agents developed for patients with endometrial cancer, human epidermal growth factor receptor 2 (HER2) targeted therapy for patients with type 2 endometrial cancer has demonstrated practice-changing efficacy [13]. Here, ERBB2 is linked to endometrial cancer.